Study Protocol for HGCSG1801: A Multicenter, Prospective, Phase II Trial of Second-Line FOLFIRI Plus Aflibercept in Patients with Metastatic Colorectal Cancer Refractory to Anti-Egfr Antibodies.
Journal of Clinical Oncology（2024）
Key words
colorectal cancer,chemotherapy,FOLFIRI,aflibercept,anti-EGFR antibodies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined